Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-27T02:13:48.728Z Has data issue: false hasContentIssue false
  • English
  • Français

Topiramate: Pharmacokinetics and Pharmacodynamics

Published online by Cambridge University Press:  18 September 2015

J.H. Schneiderman
J.H. Schneiderman*
Affiliation:
Departments of Medicine and Physiology, University of Toronto, Toronto
*
Rm 116 E.K. Jones Building, Wellesley Hospital, 160 Wellesley Street E., Toronto, Ontario, Canada M4Y 1J3
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Topiramate is a structurally novel anti-epileptic drug with at least 3 postulated mechanisms of action including: 1) potentiation of GABA responses, 2) impairment of AMPA/kainate glutamate receptors and 3) suppression of high frequency action potential firing. It has a favourable pharmacokinetic profile with rapid absorption, good bio-availability, linear pharmacokinetics, relatively long half-life and limited pharmacokinetic drug interactions. However, topiramate can reduce the estrogen component of oral contraceptive medications. Women may require birth control preparations containing 50 (Xg of estrogen. Topiramate clearance is reduced in severe renal failure and increased by enzyme-inducing antiepileptic drugs. The dose of topiramate may have to be reduced in renal failure or when withdrawing enzyme inducers.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue S3 , August 1998 , pp. S3 - S5
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Shank, RPGardocki, JF, Vaught, JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 1994; 35: 450–460.CrossRefGoogle ScholarPubMed
2.Nakamura, JTamura, S, Kanda, T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol. 1994; 254: 83–89.CrossRefGoogle ScholarPubMed
3.Edmonds, HL Jr., Jiang, YD, Zhang, PY, Shank, RP. Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemiainduced epilepsy. Life Sciences. 1996; 59: PL127-PL131CrossRefGoogle Scholar
4.Wauquier, A, Zhou, SD. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996; 24: 73–77.CrossRefGoogle ScholarPubMed
5.Coulter, DA, Sombati, S, Delorenzo, RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in culture hippocampal neurons. Epilepsia 1993; 34: 123(Abstract).Google Scholar
6.Brown, SD, Wolf, HH, Swinyard, EA, Twyman, RE, White, HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993; 34: 122–123(Abstract).Google Scholar
7.White, HS, Brown, SD, Skeen, GA, Wolf, HH, Twyman, RE. The anticonvulsant to piramate displays a unique ability to potentiate GABA-evoked currents. Epilepsia 1995; 36: 39.Google Scholar
8.Severt, L, Coulter, DA, Sombati, S, Delorenzo, RJ. Topiramate selectively blocks kainate currents in culture hippocampal neurons. Epilepsia 1995; 36: 38.Google Scholar
9.Easterling, DE, Zakszewski, T, Moyer, MD, et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1989; 29: 662.Google Scholar
10.Doose, DR, Walker, SA, Gisclon, LG,Nayak, RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36: 884–891.CrossRefGoogle ScholarPubMed
11.Reife, R. A novel antiepileptic drug. In: Shorvon, SD, Dreifuss, FE, Fish, D, Thomas, D, eds. The Treatment of Epilepsy. Cambridge: Blackwell Scientific.Cambridge: Blackwell Scientific, 1996; 471–481.Google Scholar
12.Gisclon, LG, Riffits, JM, Sica, DA, Gehr, T, Ruddley, J. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function. Pharmacol Res 1993; 10:S397.Google Scholar
13.Gisclon, LG, Curtin, CR, Kramer, LD. The steady state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994; 35:4.Google Scholar
14.Sachdeo, RC, Sachdeo, SK, Walker, SA, Kramer, LD, Nayak, RK. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996; 37: 774–780.CrossRefGoogle ScholarPubMed
15.Rosenfeld, WE, Liao, S, Kramer, LD, et al. omparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997; 38: 324–333.CrossRefGoogle Scholar
16.Rosenfeld, WE, Doose, DR, Walker, SA, Nayak, RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38: 317–323.CrossRefGoogle ScholarPubMed
17.Levy, RH, Bishop, F, Streeter, AJ. Explanation and prediction of drug interactions of topiramate using a CYP450 inhibition spectrum. Epilepsia 1995; 35: 47.Google Scholar